Collaboration

#Collaboration #Drug discovery #ELRIG #Research

Equality, diversity and inclusion at Drug Discovery 2021

The European Laboratory Research & Innovation Group (ELRIG) UK will launch its equality, diversity, and inclusion (EDI) guiding principles at Drug Discovery 2021. The principles were developed with the support of Equality, Diversity and Inclusion in Science and Health (EDIS), a coalition of organisations working to improve EDI within the science… Read More

#News

#Biopharma #Biotechnology #Collaboration #Life sciences #Technology

Why quantum computing in drug discovery needs to improve  

The Pistoia Alliance has released new results from a survey of 260 attendees from life science companies across the globe, finding that almost half classify their understanding of quantum computing (QC) technology at the beginner level (48%) only. This is followed by intermediate (29%), advanced (13%), and expert at 9%. Read More

#News #Trends & Analysis

#Cancer #Cancer research #Collaboration #Innovation

Cancer Research UK and University of Edinburgh start-up boost 

A University of Edinburgh business-support programme has partnered with Cancer Research UK to help build startup companies focused on tackling cancer.  The charity will fund up to ten participants in the second round of the university’s Data-Driven Entrepreneurship (DDE) Venture Builder Incubator, which supports postgraduate students, postdoctoral researchers and academic staff… Read More

#Cancer Research #News #Start-up Zone #Trending News

#Clinical trials #Collaboration #Covid-19 #Immunology / Virology & Vaccines #Pharmaceutical #Research

Early trial of first multivariant Covid-19 vaccine booster begins

A Phase I clinical trial of the world’s first multivariant Covid-19 vaccine has been launched by US pharmaceutical company Gritstone in collaboration with The University of Manchester UK and Manchester University NHS Foundation Trust.  Initially involving participants aged 60+, its creators say the drug, GRT-R910, can boost… Read More

#News

#Collaboration #Drug development #Drug discovery #Gene mutation #Research #Schizophrenia

This week in drug discovery (13-17 September) 

News round-up by DDW’s Megan Thomas for 13-17 September  The news in the drug discovery industry this week has demonstrated the potential that remains untapped for a number of industries at large as well as taking early steps towards future cures and treatments. DDW’s Megan Thomas has… Read More

#News #Trending News

#Biomarkers #Collaboration #Gene mutation #Gene therapy

Illumina and Merck partner to identify cancer mutations 

Illumina and Merck have partnered to develop and commercialise tests that identify genetic mutations used in the assessment of homologous recombination deficiency (HRD).   Patients whose tumours are HRD-positive may be eligible for targeted treatment by a class of precision medicines called PARP inhibitors. The HRD tests will leverage Illumina’s TruSight Oncology 500 (TSO… Read More

#News

#Collaboration #Drug discovery #Mass spectrometry / NMR #Parkinson's #Research #Schizophrenia #Therapeutics

This week in drug discovery (6-10 September) 

News round-up by DDW’s Megan Thomas for 6 – 10 September  DDW’s Megan Thomas selects five stories which showcase results, data, partnerships and research which offer a promising future for both drug development and eventual treatment of a number of diseases.   New potential therapy for… Read More

#News #Trending News

#AI #AI / data analytics / healthtech / informatics #Collaboration #Drug discovery #Molecular Biology

IBM Research and Arctoris accelerate closed loop drug discovery 

IBM Research and Arctoris are investigating the application of AI and automation to accelerate closed loop molecule discovery.   IBM Research has developed RXN for Chemistry, an online platform leveraging Natural Language Processing (NLP) architectures to automate synthetic chemistry. Representing chemical reactions via SMILES (Simplified Molecular Input Line Entry System),… Read More

#News #Trending News

#Collaboration #Covid-19 #Therapeutics

Exscientia and Gates Foundation’s antiviral therapeutics  

Exscientia has entered a four-year collaboration with the Bill & Melinda Gates Foundation to develop small molecule therapeutics that tackle the current coronavirus pandemic and help prepare for future pandemics.   The collaboration will initially focus on developing broad-spectrum coronavirus agents (e.g., SARS-CoV-2 and its variants, MERS), including accelerating Exscientia’s lead programme,… Read More

#News

#Collaboration #Covid-19 #Drug discovery #Research

This week in drug discovery (30 August – 3 September) 

News round-up by DDW’s Megan Thomas for 30 August – 3 September  DDW’s Megan Thomas has rounded up five stories in which studies, collaborations and trials pave the way towards treatments for a number of potentially fatal conditions.   1. NIH studies Covid-19 vaccine dose for… Read More

#News

#Cardiovascular disease #Collaboration #Drug discovery

Novartis collaboration has potential to improve heart health in UK 

Novartis and NHS England are to pioneer a population health management approach to address elevated LDL-C in patients with Atherosclerotic Cardiovascular Disease (ASCVD) across England.  The collaboration received positive final recommendation from the National Institute for Health and Care Excellence (NICE) for use of inclisiran in primary care for the treatment of adult patients within its licenced indication1 who… Read More

#Business & Investment #News

#Antibodies #Biotherapeutics #Collaboration #Drug discovery

Collaboration to support preclinical drug discovery research 

Fusion Antibodies has entered into a commercial collaboration with Eurofins to provide laboratories worldwide with high-quality, cost-effective and efficient services that work with one another to support biotherapeutic discovery.   Under the agreement, Fusion Antibodies will provide comprehensive pre-clinical antibody development services from discovery, engineering, and critical reagent supply to Eurofins so that… Read More

#Business & Investment #News

#Biotherapeutics #Collaboration #Funding #HIV #Pharma

This week in drug discovery (16-20 August) 

News round-up by DDW’s Megan Thomas for 16-20 August  DDW’s Megan Thomas selects five news stories which spotlight the deals, collaborations and funding keeping the industry moving forward, enabling academics and drug developers to continue with life-saving research.   1. OGT training initiative with CytoCell University … Read More

#News #Trending News

#Biologics / Biotechnology #Collaboration #Drug development

Collaboration aims to accelerate cyro-EM research 

Amgen and the University of Southern California (USC) are working together to provide researchers access to two cryo-transmission electron microscopes (cryo-EMs) – the Thermo Scientific Krios and Glacios.  Access to the two instruments in one shared location allows researchers from both institutions to combine resources to bring more speed and… Read More

#News

#Biotechnology #Collaboration #Training

OGT training initiative with CytoCell University

OGT has expanded its activities with CytoCell University, an initiative that provides training to scientists on the basics of fluorescence in situ hybridisation (FISH). CytoCell University’s FISH training and OGT aim to support scientists internationally and help customers advance genetic analysis. CytoCell University’s first module, set to be part of… Read More

#News

#Biomedicine #Collaboration #Life sciences #Pharma

Stop, collaborate and listen: podcast

This is the latest episode of the free DDW podcast, “Stop, collaborate and listen: a model for successful pharma and vendor engagement”. It covers a narrated article written for DDW and read aloud by Megan Thomas. Digital transformations are having wide-ranging and profound impacts within life sciences, creating both opportunities… Read More

#Editor's Choice #News